Clinical Trial Update: Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rosiglitazone (Avandia) to placebo in androgen-dependent prostate cancer has completed; trial results are not provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• Rosiglitazone (Avandia) (rosiglitazone)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Adenocarcinoma of the Prostate, Prostate Cancer | Phase 3 | Status: COMPLETED